MCID: LPD008
MIFTS: 63

Lipid Metabolism Disorder

Categories: Genetic diseases, Immune diseases, Liver diseases, Metabolic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lipid Metabolism Disorder

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 15
Dyslipidemia 12 54 15
Disorder of Fatty Acid Metabolism 29 71
Abnormality of Lipid Metabolism 29 6
Lipid Metabolism Disorders 42 71
Lipid Metabolism, Inborn Errors 43
Fatty Acid Metabolism Disorder 12
Disorder of Lipid Metabolism 58
Dyslipidemias 71

Classifications:

Orphanet: 58  
Inborn errors of metabolism


External Ids:

Disease Ontology 12 DOID:3146
MeSH 43 D008052
ICD10 32 E71.3
UMLS via Orphanet 72 C0154251
Orphanet 58 ORPHA309005
UMLS 71 C0023772 C0154251 C0242339 more

Summaries for Lipid Metabolism Disorder

MedlinePlus : 42 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as dyslipidemia, is related to hyperlipoproteinemia, type iii and hypolipoproteinemia. An important gene associated with Lipid Metabolism Disorder is FADS1 (Fatty Acid Desaturase 1), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Nifedipine and Mirabegron have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 74 Lipid metabolism is the synthesis and degradation of lipids in cells, involving the breakdown or storage... more...

Related Diseases for Lipid Metabolism Disorder

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 687)
# Related Disease Score Top Affiliating Genes
1 hyperlipoproteinemia, type iii 33.3 LPL LPA LIPC CETP APOE APOB
2 hypolipoproteinemia 33.1 LPL LPA COG2 CETP APOE APOC3
3 abdominal obesity-metabolic syndrome 1 33.1 SERPINE1 PPARG PPARA LPL LEP INS
4 lipodystrophy, familial partial, type 2 32.8 PPARG LEP INS ADIPOQ
5 sitosterolemia 32.8 HMGCR APOB APOA1
6 prediabetes syndrome 32.5 PPARG PPARA LEP INS CRP COG2
7 coronary artery anomaly 31.7 SERPINE1 LPA HMGCR CRP COG2 APOB
8 non-alcoholic steatohepatitis 31.7 PPARG PPARA INS ADIPOQ
9 end stage renal failure 31.6 LEP CRP COG2 APOB ADIPOQ ACE
10 chronic kidney disease 31.5 SERPINE1 LPL LPA LIPC LEP INS
11 arteries, anomalies of 31.4 SERPINE1 LPA LEP INS CRP COG2
12 sleep apnea 31.4 LEP INS CRP APOE APOB ADIPOQ
13 gestational diabetes 31.3 PPARG LEP INS CRP ADIPOQ
14 pre-eclampsia 31.3 SERPINE1 LEP INS CRP ADIPOQ ACE
15 cerebrovascular disease 31.3 SERPINE1 LPL LPA LEP INS CRP
16 peripheral artery disease 31.3 CRP APOE APOB APOA1 ACE
17 hyperandrogenism 31.3 PPARG INS ADIPOQ
18 hyperlipidemia, familial combined, 3 31.3 PPARA LPL LIPC INS COG2 CETP
19 fatty liver disease 31.3 PPARG PPARA LEP INS CRP APOB
20 hypoalphalipoproteinemia 31.3 LIPC APOA1
21 peripheral vascular disease 31.2 SERPINE1 LPA INS HMGCR CRP COG2
22 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.2 LEP INS ADIPOQ
23 anovulation 31.2 LEP INS CRP
24 fatty liver disease, nonalcoholic 1 31.2 PPARA LEP INS ADIPOQ
25 vascular disease 31.1 SERPINE1 PPARG LPL LPA LIPC LEP
26 diabetic neuropathy 31.1 LEP INS ACE
27 aortic aneurysm, familial abdominal, 1 31.1 CRP CETP APOE ACE
28 hyperinsulinism 31.0 SERPINE1 PPARG PPARA LPL LEP INS
29 acute myocardial infarction 31.0 SERPINE1 LPA INS HMGCR CRP APOB
30 leptin deficiency or dysfunction 31.0 PPARG PPARA LPL LEP INS CRP
31 eye disease 31.0 PPARA INS HMGCR CRP APOA1 ACE
32 proteasome-associated autoinflammatory syndrome 1 31.0 PPARG PPARA INS CRP ADIPOQ
33 homocysteinemia 31.0 SERPINE1 CRP APOE
34 acquired immunodeficiency syndrome 31.0 CRP APOE APOB APOA1
35 polycystic ovary syndrome 31.0 LEP INS CRP ADIPOQ
36 retinal vascular disease 31.0 INS CRP ACE
37 amyloidosis 31.0 LPA INS CRP APOE APOA1
38 pancreatitis 30.9 LPL INS CRP APOA5
39 stroke, ischemic 30.9 SERPINE1 LPA HMGCR CRP COG2 APOE
40 sleep disorder 30.9 LEP INS CRP ADIPOQ ACE
41 diabetes mellitus, insulin-dependent 30.9 LPA LEP INS CRP CETP APOB
42 bone resorption disease 30.9 LEP INS CRP
43 lipid storage disease 30.9 PPARG PPARA LEP INS APOB ADIPOQ
44 amyloidosis aa 30.8 LPA CRP APOA1
45 diabetes mellitus, noninsulin-dependent 30.8 SERPINE1 PPARG PPARA LPL LPA LIPC
46 carotid stenosis 30.8 LPA CRP APOE ADIPOQ ACE
47 acanthosis nigricans 30.8 PPARG LEP INS ADIPOQ
48 familial partial lipodystrophy 30.8 PPARG LEP INS ADIPOQ
49 macular degeneration, age-related, 1 30.8 LIPC INS CRP CETP APOE APOB
50 arteriosclerosis 30.8 SERPINE1 PPARG PPARA LPA INS HMGCR

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Hypertension, Essential Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder

Symptoms & Phenotypes for Lipid Metabolism Disorder

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 APOA1 APOA5 APOB APOC3 APOE CETP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ACE ADIPOQ APOA1 APOA5 APOB APOE
2 cardiovascular system MP:0005385 10.26 ACE ADIPOQ APOA1 APOB APOE CRP
3 growth/size/body region MP:0005378 10.21 ACE ADIPOQ APOB APOE COG2 HMGCR
4 adipose tissue MP:0005375 10.15 ACE ADIPOQ APOE INS LEP LPL
5 endocrine/exocrine gland MP:0005379 10.11 ACE ADIPOQ APOA1 APOE FADS1 INS
6 immune system MP:0005387 10.11 ACE ADIPOQ APOB APOE CRP FADS1
7 liver/biliary system MP:0005370 10.03 ACE ADIPOQ APOA1 APOB APOE HMGCR
8 integument MP:0010771 9.97 ADIPOQ APOA1 APOE INS LEP LPL
9 mortality/aging MP:0010768 9.97 ACE ADIPOQ APOB APOE COG2 FADS1
10 muscle MP:0005369 9.56 ADIPOQ APOB APOE INS LEP LPL
11 renal/urinary system MP:0005367 9.23 ACE ADIPOQ APOE INS LEP PPARA

Drugs & Therapeutics for Lipid Metabolism Disorder

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 653)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Mirabegron Approved Phase 4 223673-61-8 9865528
3
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
12
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
13
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
14
Bilberry Approved, Experimental Phase 4
15
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
16
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
17
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
18
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
19 Orange Approved Phase 4
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
22
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
23
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
24
Ciprofibrate Approved, Investigational Phase 4 52214-84-3 2763
25
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
26
Calcium polycarbophil Approved Phase 4 126040-58-2
27
Loperamide Approved Phase 4 53179-11-6 3955
28
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
29
Lopinavir Approved Phase 4 192725-17-0 92727
30
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
31
Infliximab Approved Phase 4 170277-31-3
32
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
33
Glyburide Approved Phase 4 10238-21-8 3488
34
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
35
Febuxostat Approved Phase 4 144060-53-7 134018
36
Insulin glargine Approved Phase 4 160337-95-1
37
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
38
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
39
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
40
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
41
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
42
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
43
Dulaglutide Approved, Investigational Phase 4 923950-08-7
44
Insulin aspart Approved Phase 4 116094-23-6 16132418
45
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
46
Insulin detemir Approved Phase 4 169148-63-4 5311023
47
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
48
Histamine Approved, Investigational Phase 4 51-45-6 774
49
Gliclazide Approved Phase 4 21187-98-4 3475
50
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452

Interventional clinical trials:

(show top 50) (show all 1901)
# Name Status NCT ID Phase Drugs
1 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
2 An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia Unknown status NCT00678743 Phase 4 Omacor + simvastatin
3 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
4 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
5 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
6 An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
7 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
8 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
9 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
10 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
11 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
12 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
13 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
14 Effectiveness and Safety of Low-dose vs. High-dose Rosuvastatin on Long-term Cardiovascular Events in Korean Patients After Percutaneous Coronary Intervention: 30-month, Prospective, Single-center, Randomized Trial Unknown status NCT02859480 Phase 4 Rosuvastatin 5mg;Rosuvastatin 20mg
15 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
16 What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo Unknown status NCT02606617 Phase 4 Mosapride;Placebo
17 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
18 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
19 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
20 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
21 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study) Unknown status NCT01736202 Phase 4
22 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
23 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
24 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
25 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
26 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
27 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
28 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia Completed NCT00651963 Phase 4 ezetimibe
29 A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD Completed NCT01551173 Phase 4 Fluvastatin sodium
30 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
31 Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
32 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo
33 Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers Completed NCT00171262 Phase 4 Fluvastatin
34 Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients Completed NCT00654628 Phase 4 ezetimibe (+) simvastatin
35 A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study Completed NCT01301066 Phase 4 Pitavastatin;Pravastatin
36 A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA Completed NCT01256476 Phase 4 pitavastatin;pravastatin
37 A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea Completed NCT01029522 Phase 4 Atorvastatin (Lipilou);Atorvastatin (Lipitor)
38 Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial Completed NCT01285544 Phase 4 Atorvastatin (Lipinon);Atorvastatin (Lipitor)
39 Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake Completed NCT00125125 Phase 4 Fluvastatin
40 A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study Completed NCT02057302 Phase 4 Xuezhikang capsule
41 Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study Completed NCT00405171 Phase 4 Nevirapine
42 A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome Completed NCT00385658 Phase 4 Fluvastatin extended release, fenofibrate;Fixed combination simvastatin/ezetimibe
43 Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study Completed NCT01778244 Phase 4 metformin
44 An Outcome Research on the Impact of a Disease Management Program (COACH) on the Attainment of Better Cardiovascular Risk Control in Dyslipidemic Patients at Primary Care Centers (DISSEMINATE). Completed NCT00708370 Phase 4
45 Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction Completed NCT00171327 Phase 4 valsartan, fluvastatin
46 Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents Completed NCT01502904 Phase 4 pravastatin 20mg/day after DES implantation;pitavastatin 2mg/day after DES implantation;Non-ARB /day after DES implantation;Eposartan 600mg/day after DES implantation
47 A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia Completed NCT01239004 Phase 4 Placebo;Colesevelam
48 An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untreated Subject Population) Completed NCT00332761 Phase 4 Caduet
49 A 8-week, Single Center, Randomized, Open-label, Parallel-group, Non-inferiority Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients Completed NCT03949374 Phase 4 CRESTOR, reference formulation of rosuvastatin;ROVASRO, generic formulation of rosuvastatin
50 A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients Completed NCT00928889 Phase 4 Nateglinide 120 mg;Acarbose 50 mg

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Genetic Tests for Lipid Metabolism Disorder

Genetic tests related to Lipid Metabolism Disorder:

# Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29

Anatomical Context for Lipid Metabolism Disorder

MalaCards organs/tissues related to Lipid Metabolism Disorder:

40
Liver, Heart, Kidney, Endothelial, Ovary, Testes, Thyroid

Publications for Lipid Metabolism Disorder

Articles related to Lipid Metabolism Disorder:

(show top 50) (show all 25967)
# Title Authors PMID Year
1
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. 42
31714986 2019
2
Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships. 42
31648563 2019
3
Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. 42
31618541 2019
4
Targeting dyslipidemia in the metabolic syndrome: an update. 54 61
19485929 2010
5
Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. 54 61
20339372 2010
6
Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese. 54 61
20004425 2010
7
A novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia. 54 61
20123124 2010
8
Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. 54 61
20199774 2010
9
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. 54 61
20388526 2010
10
Ala54Thr polymorphism of fatty acid-binding protein 2 gene and fasting blood lipids: a meta-analysis. 54 61
20047744 2010
11
Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. 54 61
19922962 2010
12
Is there a link between inflammation and abnormal lipoprotein profile in Sjögren's syndrome? 54 61
20378384 2010
13
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. 54 61
20005515 2010
14
Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis. 54 61
20226795 2010
15
[Statins in the management of acute coronary syndrome]. 54 61
20387563 2010
16
Hormone and pharmaceutical regulation of ASP production in 3T3-L1 adipocytes. 54 61
20069551 2010
17
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. 54 61
19965597 2010
18
Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. 54 61
19922965 2010
19
Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. 54 61
20173020 2010
20
Concordance of two multiple analytical approaches demonstrate that interaction between BMI and ADIPOQ haplotypes is a determinant of LDL cholesterol in a general French population. 54 61
20186155 2010
21
Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study. 54 61
20200337 2010
22
Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. 54 61
19819456 2010
23
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. 54 61
20016053 2010
24
Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. 54 61
19933370 2010
25
Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. 54 61
19781705 2010
26
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 54 61
20158099 2010
27
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 54 61
19910639 2010
28
Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. 54 61
19683050 2010
29
Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. 54 61
19699495 2010
30
[Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors]. 54 61
20514101 2010
31
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. 54 61
20104931 2010
32
The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. 54 61
19639021 2010
33
Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. 54 61
20425272 2010
34
[A case-control study on risk factors of type 2 diabetes mellitus related chronic complications in Baoding city]. 54 61
20193318 2009
35
Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. 54 61
19778946 2009
36
Decrease in FASN expression in adipose tissue of hypertensive individuals. 54 61
19851294 2009
37
Effects of weight loss on lipid transfer proteins in morbidly obese women. 54 61
19789902 2009
38
Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy. 54 61
19501863 2009
39
Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. 54 61
19797171 2009
40
Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. 54 61
19749155 2009
41
Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. 54 61
19821969 2009
42
Increase in gamma-glutamyltransferase level and development of established cardiovascular risk factors and diabetes in Japanese adults. 54 61
19419267 2009
43
[Secondary dyslipidaemia after oral contraceptives]. 54 61
19947236 2009
44
Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. 54 61
20031629 2009
45
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese. 54 61
19570551 2009
46
Forkhead box transcription factor O1 inhibits cholesterol 7alpha-hydroxylase in human hepatocytes and in high fat diet-fed mice. 54 61
19463968 2009
47
Splenomegaly with sea-blue histiocytosis, dyslipidemia, and nephropathy in a patient with lecithin-cholesterol acyltransferase deficiency: a clinicopathologic correlation. 54 61
19592052 2009
48
Determination of the Apo E genotype using LightCycler Apo E mutation detection kit. 54 61
19891383 2009
49
Metabolic consequences of peritoneal dialysis treatment. 54 61
19859052 2009
50
A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. 54 61
19750004 2009

Variations for Lipid Metabolism Disorder

ClinVar genetic disease variations for Lipid Metabolism Disorder:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APOE NM_000041.4(APOE):c.461G>T (p.Arg154Leu)SNV Likely pathogenic 375636 rs200703101 19:45412014-45412014 19:44908757-44908757

Expression for Lipid Metabolism Disorder

Search GEO for disease gene expression data for Lipid Metabolism Disorder.

Pathways for Lipid Metabolism Disorder

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 PPARG PPARA LPL LPA LIPC INS
2
Show member pathways
12.75 PPARG PPARA LPL LEP HMGCR FADS1
3
Show member pathways
12.55 LPL APOE APOC3 APOB APOA1
4
Show member pathways
12.35 PPARG LEP INS HMGCR ADIPOQ
5
Show member pathways
12.34 LPL LPA LIPC CETP APOE APOC3
6
Show member pathways
12.22 LPL APOE APOC3 APOB APOA1
7
Show member pathways
12.21 SERPINE1 INS CRP APOE APOB APOA1
9 11.92 SERPINE1 PPARG PPARA LPL LEP INS
10 11.62 PPARG LPL INS HMGCR
11 11.57 PPARA LEP ADIPOQ
12
Show member pathways
11.39 LPL LPA LIPC HMGCR CETP APOE
13 11.38 PPARG PPARA LPL APOC3 APOA5 APOA1
14 11.1 PPARG LEP ADIPOQ
15 11.08 PPARA APOC3 APOA5 APOA1
16 11.03 PPARG LEP ADIPOQ

GO Terms for Lipid Metabolism Disorder

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.2 SERPINE1 LPL LPA LIPC LEP INS
2 extracellular space GO:0005615 10.1 SERPINE1 LPL LIPC LEP INS CRP
3 collagen-containing extracellular matrix GO:0062023 9.91 SERPINE1 APOE APOC3 APOA1 ADIPOQ
4 endoplasmic reticulum lumen GO:0005788 9.91 LIPC INS APOE APOB APOA5 APOA1
5 early endosome GO:0005769 9.88 APOE APOC3 APOB APOA5 APOA1
6 low-density lipoprotein particle GO:0034362 9.71 APOE APOB APOA5 APOA1
7 intermediate-density lipoprotein particle GO:0034363 9.67 APOE APOC3 APOB APOA1
8 endocytic vesicle lumen GO:0071682 9.63 APOE APOB APOA1
9 high-density lipoprotein particle GO:0034364 9.63 LIPC CETP APOE APOB APOA5 APOA1
10 spherical high-density lipoprotein particle GO:0034366 9.52 APOC3 APOA1
11 discoidal high-density lipoprotein particle GO:0034365 9.49 APOE APOA1
12 very-low-density lipoprotein particle GO:0034361 9.43 LPL APOE APOC3 APOB APOA5 APOA1
13 chylomicron GO:0042627 9.1 LPL APOE APOC3 APOB APOA5 APOA1

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 lipid transport GO:0006869 10.08 LPA CETP APOE APOC3 APOB APOA5
2 cellular protein metabolic process GO:0044267 10.06 INS APOE APOB APOA5 APOA1
3 regulation of lipid metabolic process GO:0019216 10.05 PPARG PPARA HMGCR FADS1 APOA5 APOA1
4 steroid metabolic process GO:0008202 10.03 HMGCR CETP APOE APOB APOA1
5 response to nutrient GO:0007584 10.02 PPARG LEP HMGCR FADS1 APOA1 ADIPOQ
6 fatty acid metabolic process GO:0006631 10.01 PPARG PPARA LPL FADS1
7 retinoid metabolic process GO:0001523 10 LPL APOE APOC3 APOB APOA1
8 cholesterol metabolic process GO:0008203 10 LIPC LEP HMGCR CETP APOE APOB
9 negative regulation of inflammatory response GO:0050728 9.98 PPARA APOE APOA1 ADIPOQ
10 lipid catabolic process GO:0016042 9.97 LPL LIPC APOC3 APOB
11 triglyceride metabolic process GO:0006641 9.97 LPL CETP APOE APOC3 APOA5
12 glucose homeostasis GO:0042593 9.96 PPARG LEP INS ADIPOQ
13 response to organic substance GO:0010033 9.92 PPARG FADS1 APOB
14 circadian rhythm GO:0007623 9.92 SERPINE1 LEP ADIPOQ
15 cholesterol efflux GO:0033344 9.92 APOE APOC3 APOB APOA5 APOA1
16 cholesterol transport GO:0030301 9.91 LIPC CETP APOB APOA1
17 triglyceride catabolic process GO:0019433 9.91 LPL LIPC APOC3 APOB APOA5
18 response to insulin GO:0032868 9.9 PPARA LEP FADS1
19 fatty acid biosynthetic process GO:0006633 9.9 LPL LIPC FADS1
20 regulation of blood pressure GO:0008217 9.89 PPARG LEP ACE
21 glucose metabolic process GO:0006006 9.89 LEP INS ADIPOQ
22 phospholipid efflux GO:0033700 9.89 APOE APOC3 APOA5 APOA1
23 reverse cholesterol transport GO:0043691 9.89 LIPC CETP APOE APOC3 APOA1
24 chylomicron assembly GO:0034378 9.88 APOE APOC3 APOB APOA1
25 high-density lipoprotein particle remodeling GO:0034375 9.88 LIPC CETP APOE APOC3 APOA1
26 lipid homeostasis GO:0055088 9.87 PPARG CETP APOE
27 negative regulation of MAP kinase activity GO:0043407 9.86 HMGCR APOE ADIPOQ
28 cholesterol biosynthetic process GO:0006695 9.86 HMGCR APOA5 APOA1
29 chylomicron remnant clearance GO:0034382 9.86 LIPC APOE APOC3 APOB
30 cholesterol homeostasis GO:0042632 9.86 LPL LIPC CETP APOE APOC3 APOB
31 negative regulation of protein secretion GO:0050709 9.83 INS HMGCR APOE
32 positive regulation of cholesterol efflux GO:0010875 9.83 APOE APOA1 ADIPOQ
33 low-density lipoprotein particle remodeling GO:0034374 9.83 LPA LIPC CETP APOE APOB
34 phosphatidylcholine metabolic process GO:0046470 9.82 CETP APOA5 APOA1
35 high-density lipoprotein particle assembly GO:0034380 9.82 APOE APOA5 APOA1
36 negative regulation of blood vessel diameter GO:0097756 9.81 INS HMGCR CRP
37 positive regulation of cholesterol esterification GO:0010873 9.81 APOE APOA5 APOA1
38 regulation of Cdc42 protein signal transduction GO:0032489 9.8 APOE APOC3 APOA1
39 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.8 PPARG PPARA CRP CETP ADIPOQ
40 lipoprotein metabolic process GO:0042157 9.8 PPARA APOE APOC3 APOB APOA5 APOA1
41 lipoprotein biosynthetic process GO:0042158 9.79 APOE APOB APOA1
42 regulation of intestinal cholesterol absorption GO:0030300 9.79 LEP APOA5 APOA1
43 chylomicron remodeling GO:0034371 9.77 LPL APOE APOC3 APOB APOA1
44 positive regulation of lipid biosynthetic process GO:0046889 9.74 INS APOE
45 long-chain fatty acid transport GO:0015909 9.74 PPARG APOE
46 phospholipid homeostasis GO:0055091 9.74 CETP APOA1
47 positive regulation of lipoprotein lipase activity GO:0051006 9.74 APOA5 APOA1
48 positive regulation of lipid storage GO:0010884 9.74 LPL APOB
49 response to dietary excess GO:0002021 9.74 LEP APOE
50 high-density lipoprotein particle clearance GO:0034384 9.73 APOE APOA1

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.95 SERPINE1 LPL LEP APOE APOA1 ADIPOQ
2 phospholipid binding GO:0005543 9.8 APOE APOC3 APOB APOA5 APOA1
3 lipid binding GO:0008289 9.8 PPARG PPARA CETP APOE APOC3 APOA5
4 cholesterol binding GO:0015485 9.76 CETP APOC3 APOA5 APOA1
5 drug binding GO:0008144 9.74 PPARG PPARA ACE
6 phosphatidylcholine binding GO:0031210 9.7 CETP APOA5 APOA1
7 apolipoprotein binding GO:0034185 9.67 LPL LPA LIPC
8 heparin binding GO:0008201 9.63 LPL LPA LIPC APOE APOB APOA5
9 lipid transporter activity GO:0005319 9.62 CETP APOE APOB APOA1
10 lipoprotein particle binding GO:0071813 9.61 LPL APOE APOA1
11 lipase inhibitor activity GO:0055102 9.56 APOC3 APOA1
12 lipase binding GO:0035473 9.55 APOB APOA5
13 high-density lipoprotein particle receptor binding GO:0070653 9.54 APOC3 APOA1
14 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.54 APOE APOA5 APOA1
15 triglyceride binding GO:0017129 9.51 LPL CETP
16 low-density lipoprotein particle receptor binding GO:0050750 9.26 CRP APOE APOB APOA5
17 intermembrane cholesterol transfer activity GO:0120020 8.92 CETP APOE APOB APOA1

Sources for Lipid Metabolism Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet